Symptoms of overexposure include severe leukopenia, anemia, thrombocytopenia, and a hemorrhagic diathesis with subsequent delayed bleeding may develop. Death may follow. The most common adverse reactions (?5%) of the topical formulation are dermatitis, pruritus, bacterial skin infection, skin ulceration or blistering, and hyperpigmentation. The oral LD50 for a rat is 10 mg/kg.
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.
The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Mechlorethamine. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Mechlorethamine. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mechlorethamine. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mechlorethamine. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mechlorethamine. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mechlorethamine. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Mechlorethamine. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mechlorethamine. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mechlorethamine. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mechlorethamine. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Mechlorethamine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mechlorethamine. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Mechlorethamine. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mechlorethamine. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mechlorethamine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Mechlorethamine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Mechlorethamine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Mechlorethamine. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Mechlorethamine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mechlorethamine. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Mechlorethamine. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mechlorethamine. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mechlorethamine. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mechlorethamine. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mechlorethamine. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mechlorethamine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Mechlorethamine. |
| Cladribine | Mechlorethamine may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mechlorethamine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Mechlorethamine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mechlorethamine. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mechlorethamine. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mechlorethamine. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mechlorethamine. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mechlorethamine. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Mechlorethamine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Mechlorethamine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Mechlorethamine. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Mechlorethamine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mechlorethamine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mechlorethamine. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Mechlorethamine. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Mechlorethamine. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mechlorethamine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mechlorethamine. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Mechlorethamine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Mechlorethamine. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mechlorethamine. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mechlorethamine. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Mechlorethamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Mechlorethamine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mechlorethamine. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mechlorethamine. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mechlorethamine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Mechlorethamine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mechlorethamine. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mechlorethamine. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Mechlorethamine. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Mechlorethamine. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Mechlorethamine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Mechlorethamine. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Mechlorethamine. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Mechlorethamine. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mechlorethamine. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mechlorethamine. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mechlorethamine. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mechlorethamine. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Mechlorethamine. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Mechlorethamine. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Mechlorethamine. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Mechlorethamine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mechlorethamine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mechlorethamine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Mechlorethamine. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Mechlorethamine. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Carboplatin. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Capecitabine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Idarubicin. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ifosfamide. |
| Estramustine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mitoxantrone. |